February 26, 2024 — More than 6 million Americans live with heart failure, and about half have an enlarged left ventricle, which causes stress on the heart and less blood pumped with each heartbeat. The Ohio State University Wexner Medical Center is the first in central Ohio to take part in a global clinical trial to use a novel therapy to reduce the size of the left ventricle without open-heart surgery.
“Certain patients with heart failure from reduced left ventricular ejection function can remain symptomatic despite optimal medical management. Patients may experience trouble breathing and fatigue, and at times require hospitalization. This novel therapy is designed to improve the structure and function of the heart and provide relief for patients who continue to have symptoms,” said Konstantinos Dean Boudoulas, MD, an interventional cardiologist and principal investigator of the CORCINCH-HF trial at Ohio State.
Boudoulas performed the first procedure on Jan. 31 along with Scott Lilly, MD, interventional cardiologist, and Thura Harfi, MD, a cardiologist specializing in imaging. The patient was a 48-year-old Columbus man with congestive heart failure and persistent symptoms despite medical therapy.
During the minimally invasive procedure, the doctors threaded a catheter from the groin to the heart. They attached an implant to the inner wall of the left ventricle and cinched it to reduce the size of the left ventricle and strengthen the heart wall. Two years ago, the FDA granted breakthrough device designation for the AccuCinch ventricular restoration system to expedite device access for life-threatening and debilitating diseases.
“We are fortunate to be in a position to participate in this pivotal trial, as well as a variety of other novel clinical trials, evaluating groundbreaking therapies,” Boudoulas said.
For more information: clinicaltrials.gov
Related coverage:
Ancora Heart AccuCinch System Shows Positive 12 Month Outcomes in Multi-study Analysis
April 16, 2024 
